206 related articles for article (PubMed ID: 27505721)
1. FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists.
Li X; Stanislaus S; Asuncion F; Niu QT; Chinookoswong N; Villasenor K; Wang J; Wong P; Boyce R; Dwyer D; Han CY; Chen MM; Liu B; Stolina M; Ke HZ; Ominsky MS; Véniant MM; Xu J
J Bone Miner Res; 2017 Apr; 32(4):834-845. PubMed ID: 27505721
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ.
Wei W; Dutchak PA; Wang X; Ding X; Wang X; Bookout AL; Goetz R; Mohammadi M; Gerard RD; Dechow PC; Mangelsdorf DJ; Kliewer SA; Wan Y
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3143-8. PubMed ID: 22315431
[TBL] [Abstract][Full Text] [Related]
3. Thiazolidinediones are potent inducers of fibroblast growth factor 21 expression in the liver.
Oishi K; Tomita T
Biol Pharm Bull; 2011; 34(7):1120-1. PubMed ID: 21720023
[TBL] [Abstract][Full Text] [Related]
4. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance.
Hale C; Chen MM; Stanislaus S; Chinookoswong N; Hager T; Wang M; Véniant MM; Xu J
Endocrinology; 2012 Jan; 153(1):69-80. PubMed ID: 22067317
[TBL] [Abstract][Full Text] [Related]
5. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
6. FGF21 Protects the Blood-Brain Barrier by Upregulating PPARγ via FGFR1/β-klotho after Traumatic Brain Injury.
Chen J; Hu J; Liu H; Xiong Y; Zou Y; Huang W; Shao M; Wu J; Yu L; Wang X; Wang X; Lin L
J Neurotrauma; 2018 Sep; 35(17):2091-2103. PubMed ID: 29648978
[TBL] [Abstract][Full Text] [Related]
7. Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice.
Barbieri M; Di Filippo C; Esposito A; Marfella R; Rizzo MR; D'Amico M; Ferraraccio F; Di Ronza C; Duan SZ; Mortensen RM; Rossi F; Paolisso G
PLoS One; 2012; 7(4):e35999. PubMed ID: 22563432
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones.
Dutchak PA; Katafuchi T; Bookout AL; Choi JH; Yu RT; Mangelsdorf DJ; Kliewer SA
Cell; 2012 Feb; 148(3):556-67. PubMed ID: 22304921
[TBL] [Abstract][Full Text] [Related]
9. The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-α agonist-induced amelioration of metabolic disorders in obese mice.
Goto T; Hirata M; Aoki Y; Iwase M; Takahashi H; Kim M; Li Y; Jheng HF; Nomura W; Takahashi N; Kim CS; Yu R; Seno S; Matsuda H; Aizawa-Abe M; Ebihara K; Itoh N; Kawada T
J Biol Chem; 2017 Jun; 292(22):9175-9190. PubMed ID: 28404815
[TBL] [Abstract][Full Text] [Related]
10. Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats.
Törüner F; Akbay E; Cakir N; Sancak B; Elbeg S; Taneri F; Aktürk M; Karakoç A; Ayvaz G; Arslan M
Horm Metab Res; 2004 Apr; 36(4):226-30. PubMed ID: 15114521
[TBL] [Abstract][Full Text] [Related]
11. New PPARγ partial agonist improves obesity-induced metabolic alterations and atherosclerosis in LDLr(-/-) mice.
Silva JC; César FA; de Oliveira EM; Turato WM; Tripodi GL; Castilho G; Machado-Lima A; de Las Heras B; Boscá L; Rabello MM; Hernandes MZ; Pitta MG; Pitta IR; Passarelli M; Rudnicki M; Abdalla DS
Pharmacol Res; 2016 Feb; 104():49-60. PubMed ID: 26706782
[TBL] [Abstract][Full Text] [Related]
12. Circadian expression of FGF21 is induced by PPARalpha activation in the mouse liver.
Oishi K; Uchida D; Ishida N
FEBS Lett; 2008 Oct; 582(25-26):3639-42. PubMed ID: 18840432
[TBL] [Abstract][Full Text] [Related]
13. Liver-enriched transcription factor CREBH interacts with peroxisome proliferator-activated receptor α to regulate metabolic hormone FGF21.
Kim H; Mendez R; Zheng Z; Chang L; Cai J; Zhang R; Zhang K
Endocrinology; 2014 Mar; 155(3):769-82. PubMed ID: 24424044
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone increases the expression of peroxisome proliferator-activated receptor-gamma target genes in adipose tissue, liver, and skeletal muscle in the sheep fetus in late gestation.
Muhlhausler BS; Morrison JL; McMillen IC
Endocrinology; 2009 Sep; 150(9):4287-94. PubMed ID: 19520784
[TBL] [Abstract][Full Text] [Related]
15. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
16. Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21.
Mai K; Andres J; Biedasek K; Weicht J; Bobbert T; Sabath M; Meinus S; Reinecke F; Möhlig M; Weickert MO; Clemenz M; Pfeiffer AF; Kintscher U; Spuler S; Spranger J
Diabetes; 2009 Jul; 58(7):1532-8. PubMed ID: 19401423
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.
Xu J; Lloyd DJ; Hale C; Stanislaus S; Chen M; Sivits G; Vonderfecht S; Hecht R; Li YS; Lindberg RA; Chen JL; Jung DY; Zhang Z; Ko HJ; Kim JK; Véniant MM
Diabetes; 2009 Jan; 58(1):250-9. PubMed ID: 18840786
[TBL] [Abstract][Full Text] [Related]
18. PPARalpha is a key regulator of hepatic FGF21.
Lundåsen T; Hunt MC; Nilsson LM; Sanyal S; Angelin B; Alexson SE; Rudling M
Biochem Biophys Res Commun; 2007 Aug; 360(2):437-40. PubMed ID: 17601491
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
[TBL] [Abstract][Full Text] [Related]
20. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Hennuyer N; Tailleux A; Torpier G; Mezdour H; Fruchart JC; Staels B; Fiévet C
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1897-902. PubMed ID: 15994444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
